PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'From the Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children\'s Hospital (A.M.S.).\', \'Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.\', \'Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.\', \'Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.\', \'Division of Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD (T.M.B.).\', \'Department of Pediatrics, University of Washington School of Medicine and Division of Nephrology, Seattle Children\'s Hospital (J.T.F.).\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1161/HYPERTENSIONAHA.120.15291
?:hasPublicationType
?:journal
  • Hypertension (Dallas, Tex. : 1979)
is ?:pmid of
?:pmid
?:pmid
  • 32367746
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all